Skip to main content
Onxeo logo

Onxeo — Investor Relations & Filings

Ticker · ALONX ISIN · FR0010095596 LEI · 96950018AS30IUG0V528 PA Manufacturing
Open in API
Filings indexed 661 across all filing types
Latest filing 2015-07-08 Regulatory Filings
Country FR France
Listing PA ALONX

About Onxeo

https://www.onxeo.com/

Valerio Therapeutics, formerly Onxeo, is a biotechnology company developing next-generation precision-guided therapies for complex and underserved diseases. The company's core technology is its proprietary V-Body platform, which is based on two fully synthetic single-domain antibody (sdAb) libraries. This platform is engineered to create advanced drug conjugates that enable deep tissue penetration and highly precise therapeutic delivery. By integrating innovative target identification, antibody engineering, and cutting-edge linker and payload technologies, Valerio Therapeutics aims to develop treatments with superior efficacy and target engagement. The company's strategy involves advancing its therapeutic candidates to key development milestones before pursuing strategic partnerships for co-development and out-licensing.

Recent filings

Filing Released Lang Actions
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is a press release dated July 8, 2015, announcing that Onxeo SA confirms its eligibility for the PEA-PME investment scheme in France. This announcement relates to the company's structure and regulatory compliance regarding investment vehicles, but it is not a core financial report (like 10-K or IR), a management change (MANG), or a dividend notice (DIV). It is a specific regulatory/corporate update that doesn't fit neatly into the primary financial filing categories. Since it is a specific announcement that doesn't match the detailed definitions (AGM-R, 10-K, ER, etc.), the most appropriate fallback category is Regulatory Filings (RNS), which covers general regulatory announcements.
2015-07-08 French
Communicated under the obligation to provide permanent information / Other communications
Investor Presentation Classification · 1% confidence The document is a press release from Onxeo S.A. dated July 8, 2015, announcing its schedule for meetings with investors and the financial community during the second half of 2015. It lists specific dates, times, and locations for analyst meetings, conferences, and audio/web conferences. This type of announcement, detailing future engagements with investors, is best classified as an Investor Presentation or related communication, but given the specific options, it most closely aligns with scheduling investor-facing events. Since there isn't a specific 'Investor Schedule' code, I must evaluate the closest fit. It is not a formal report (10-K, IR, ER), nor a transcript (CT). It is an announcement intended for investors. The closest category that covers investor-focused communications, especially those detailing future engagement opportunities, is 'Investor Presentation' (IP), although this document is strictly a schedule announcement. However, given the context of financial reporting categories, this is a proactive communication aimed at investor relations. If the document were announcing the *content* of a presentation, IP would be perfect. Since it is an announcement *about* meetings, and it is short and informational, it could potentially be RNS (Regulatory Filings) as a general announcement. But because the core subject is 'meetings with the financial community' and 'investor meeting', IP is the most contextually relevant choice among the specific options provided, as it relates directly to investor engagement strategy.
2015-07-08 English
Communicated under the obligation to provide permanent information / Other communications
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document explicitly states its purpose in the title: "Disclosure of total number of voting rights and number of shares in the capital at June 30, 2015." It cites French commercial code and AMF regulations, and provides a table detailing the total number of outstanding shares and voting rights as of a specific date. This content directly relates to the official disclosure of voting rights and share structure, which aligns best with the 'Declaration of Voting Results & Voting Rights Announcements' category (DVA), as it is a formal declaration regarding voting rights.
2015-07-07 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is titled "Informations relatives au nombre total de droits de vote et d'actions composant le capital au 30 juin 2015" (Information relating to the total number of voting rights and shares comprising the capital as of June 30, 2015). It explicitly cites French commercial code (Code de commerce) and AMF regulations (Autorité des Marchés Financiers) regarding the disclosure of total voting rights and shares. This type of mandatory periodic disclosure, detailing the total number of shares and voting rights, is a specific regulatory filing requirement, often related to capital structure updates or general corporate compliance, but it does not fit perfectly into the defined categories like 10-K, ER, or DIV. Since it is a mandatory regulatory disclosure that doesn't match a more specific category (like DIRS for director dealing or MRQ for major shareholding changes), the most appropriate fallback category is Regulatory Filings (RNS). The document length is short (2121 chars), but it contains the required data directly, not just an announcement of a report.
2015-07-07 French
Communiqués en période d’offre / Autres communiqués
Legal Proceedings Report Classification · 1% confidence The document is a press release dated June 30, 2015, announcing that Onxeo SA presented positive Phase II trial results for Validive® at the MASCC/ISOO international symposium. It details the presentation, the discussion with the Expert Committee regarding Phase III design, and provides background information on the condition (oral mucositis) and the conference. This format—a formal announcement detailing recent corporate/clinical events, often including forward-looking statements and contact information—is characteristic of an Earnings Release (ER) or a general press release announcing significant operational/clinical milestones. Since it is not a full financial report (10-K or IR), a transcript (CT), or a specific regulatory filing like DIRS or DIV, the most appropriate classification for a press release announcing key clinical/business updates is 'Earnings Release' (ER), as these often cover key operational highlights outside of formal quarterly reporting periods, or 'Regulatory Filing' (RNS) if it were less specific. Given the focus on presenting clinical results and planning the next phase, ER is a strong fit for a major operational update announcement, though RNS is also plausible as a general announcement. However, since it is a detailed announcement of results presentation and future plans, it functions similarly to an ER announcing operational progress. I will classify it as ER based on the content being a major operational/clinical update announcement.
2015-06-30 French
Communications during bidding periods / Other releases
Legal Proceedings Report Classification · 1% confidence The document is a press release dated June 30, 2015, detailing the presentation of Phase II clinical trial results for Validive® at a medical symposium (MASCC/ISOO) and subsequent discussions with an International Advisory Board regarding Phase III trial design. It focuses on scientific/clinical updates and advisory meetings, not formal regulatory financial filings (like 10-K, MRQ, or ER). It is not a transcript (CT), a formal audit report (AR), or a general regulatory announcement (RNS). Since it details scientific progress and advisory input, it most closely aligns with general Investor Information, but none of the specific codes fit perfectly. However, given the context of presenting clinical data and discussing future development plans, it is a form of communication aimed at investors and the medical community about the product pipeline. It is not a formal Investor Presentation (IP) which usually contains broader strategic slides, nor is it a Management Discussion & Analysis (MDA). Since it is a detailed announcement about clinical progress and advisory input, and does not fit the other specific categories, it is best classified as a general Regulatory Filing (RNS) as a fallback for non-standard corporate/scientific updates, although it shares characteristics with an Investor Presentation (IP) summary. Given the focus on presenting trial results and advisory board input, which is often part of broader investor communications, I will lean towards RNS as the most appropriate catch-all for this type of scientific press release that isn't a formal financial report or a dedicated presentation deck.
2015-06-30 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.